Recombinant factor VIIa (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark) appears effective and relatively safe for the treatment of bleeding and for surgical prophylaxis in patients with Glanzmann thrombasthenia as reported to the International Registry on rFVIIa and Congenital Platelet Disorders. One of the shortcomings of the Registry data is the heterogeneity of treatment protocol, including dosage, number of doses used, duration of treatment before declaration of failure, and mode of rFVIIa administration (bolus v continuous infusion). The data are not yet sufficient to define optimal regimens for various indications such as the type of bleeding or the type of procedures. The place of this drug compared to platelet transfusion in the overall management of patients with Glanzmann thrombasthenia will need to be determined in relationship to a number of challenges and unresolved issues in the clinical care of these patients. These issues include: how to improve local measures for patients with mucosal bleeds, optimal management of young women during menarche, optimal platelet transfusion regimens for various indications, the relationship between antiplatelet antibodies detected by monoclonal antibody-specific immobilization of platelet antigens (MAIPA) and effectiveness of platelet transfusion, whether there are other biological tests that may correlate with effectiveness of platelet transfusion, and management of pregnancy and delivery regarding antiplatelet immunization.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0037-1963(01)90143-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a simplified platelet cryopreservation method: An in vitro investigation of reducing the DMSO concentration to allow administration without its pre-transfusion removal.
Vox Sang
January 2025
Research and Development, Australian Red Cross Lifeblood, Alexandria, New South Wales, Australia.
Background And Objectives: The most widely used method of platelet cryopreservation requires the addition of 5%-6% dimethylsulphoxide (DMSO), followed by its pre-freeze removal via centrifugation, to minimize toxicity. However, this adds complexity to the pre-freeze and post-thaw processing. Accordingly, the aim of this study was to simplify platelet cryopreservation by reducing the DMSO concentration and omitting the requirement for pre-transfusion removal.
View Article and Find Full Text PDFEfficacy of eribulin monotherapy for bone marrow carcinomatosis of breast cancer in a patient with Werner syndrome.
Geriatr Gerontol Int
January 2025
Department of Medical Oncology, Sapporo Medical University, Sapporo, Japan.
Various complications and potential risks of serious adverse events lessens the intensity of chemotherapy in patients with Werner syndrome. Bone marrow carcinomatosis of breast cancer was developed in a patient with Werner syndrome. Eribulin proved well tolerated and effective in improving severe thrombocytopenia, leading to platelet transfusion-free status.
View Article and Find Full Text PDFDevelopment of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection.
Hepatol Int
January 2025
Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China.
Article Synopsis
- The study focused on evaluating the outcomes of liver resection in patients with large hepatocellular carcinoma (HCC), emphasizing the challenge of surgical treatment and the poor prognosis associated with this condition.
- Researchers analyzed data from 1710 large HCC patients to create predictive models for surgical risk, overall survival, and recurrence-free survival using regression analysis in both training and validation cohorts.
- Key factors identified included platelet count, tumor characteristics, and liver function metrics, and the models demonstrated good predictive capability, with C-index values ranging from 0.675 to 0.773, indicating their effectiveness in forecasting patient outcomes post-surgery.
[Autologous Stem-Cell Transplantation without Transfusion Support in Jehovah's Witness Patients. A case series].
Rev Med Chil
June 2024
Servicio de Medicina física y Rehabilitación, Hospital del Salvador, Santiago, Chile.
Article Synopsis
- Autologous Stem-Cell Transplantation (ASTC) is effective for treating certain blood cancers but can cause severe side effects due to intense chemotherapy.
- The study presents a protocol for performing ASTC without transfusions, catering to patients who decline blood products, such as Jehovah's Witnesses (JW).
- In a small trial with four patients (two with multiple myeloma and two with lymphomas), no serious complications occurred, and all patients remained alive and well at the time of reporting, showcasing the viability of the transfusion-free approach.
Analysis of the effect of initial hemostasis resuscitation with recombinant human coagulation factor VII a on the treatment of postoperative hemorrhage in cardiac surgery.
J Cardiothorac Surg
January 2025
Cardiac Surgery Critical Care Center Inpatient Ward 1, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Objective: To investigate the effectiveness of initial hemostatic resuscitation(IHR) on the treatment of bleeding with recombinant human coagulation factor VIIa after cardiac surgery.
Methods: The clinical data of patients who received rFVIIa hemostatic treatment after cardiac surgery at Beijing Anzhen Hospital, Capital Medical University, from January 1, 2021, to December 31, 2021 were retrospectively collected. A total of 152 cases were included in the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!